6,541 Shares in BioNTech SE (NASDAQ:BNTX) Acquired by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,541 shares of the company's stock, valued at approximately $777,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Candriam S.C.A. increased its position in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after buying an additional 418,695 shares during the period. Point72 Asset Management L.P. lifted its stake in BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock worth $25,900,000 after acquiring an additional 178,981 shares during the last quarter. Finally, abrdn plc increased its stake in BioNTech by 334.4% in the third quarter. abrdn plc now owns 225,992 shares of the company's stock valued at $26,841,000 after purchasing an additional 173,969 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

BioNTech stock traded down $2.33 during midday trading on Friday, reaching $118.39. 518,887 shares of the stock traded hands, compared to its average volume of 815,873. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.38 billion, a price-to-earnings ratio of -56.94 and a beta of 0.26. The firm has a fifty day moving average price of $113.69 and a two-hundred day moving average price of $98.50.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 earnings per share. On average, equities research analysts forecast that BioNTech SE will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

BNTX has been the topic of several recent research reports. Bank of America boosted their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, September 16th. TD Cowen reduced their price target on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. HSBC upped their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Finally, JPMorgan Chase & Co. reduced their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a research note on Tuesday. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.